Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 5Terminated 2Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 57Myelodysplastic Syndromes 33Leukemia, Myelomonocytic, Chronic 16Leukemia 15Recurrence 8Multiple Myeloma 8Neoplasms 6Primary Myelofibrosis 5Myeloproliferative Disorders 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma, Follicular 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm, Residual 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid 2Hodgkin Disease 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Cyclophosphamide 24Mycophenolic Acid 15fludarabine phosphate 14fludarabine 13Whole-Body Irradiation 13Tacrolimus 12Rituximab 12Melphalan 12Filgrastim 11Cyclosporine 11Busulfan 11Radiotherapy 10Peripheral Blood Stem Cell Transplantation 10Antilymphocyte Serum 10Methotrexate 9Doxorubicin 9Gemcitabine 8Etoposide 8Brentuximab Vedotin 8Sirolimus 7pembrolizumab 6Vinblastine 6Nivolumab 6Methylprednisolone 6Granulocyte Colony-Stimulating Factor 6Alemtuzumab 6Dacarbazine 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Carmustine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hodgkin Disease × Azacitidine × Clear all
NCT01908387 2015-07-28

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Celgene

Phase 1 Terminated
2 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Mirati Therapeutics Inc.

Phase 2 Terminated
23 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡